KM-233

KM-233 is a novel cannabinoid receptor agonist developed as a lead platform for the treatment of glioblastoma multiforme (GBM). It is a classical-based cannabinoid ligand designed to optimize biopharmaceutical properties for central nervous system (CNS) malignancies. In preclinical studies using U87MG human GBM cells, KM-233 demonstrated the ability to alter phosphorylation profiles of key signaling pathways, including MEK, ERK1/2, Akt, and STAT3. Its mechanism of action involves inducing mitochondrial depolarization, activating caspase-3, and causing significant cytoskeletal and organelle redistribution (Golgi-ER). In vivo orthotopic models have shown significant tumor size reduction, suggesting potential efficacy as an antineoplastic agent for high-grade gliomas.